1 |
June CH, Sadelain M. Chimeric antigen receptor therapy[J]. N Engl J Med, 2018, 379(1):64-73.
|
2 |
Wang L, Tan Su Yin E, Zhao H, et al. CAR-T cells: the Chinese experience[J]. Expert Opin Biol Ther, 2020, 20(11):1293-1308.
|
3 |
Wei J, Guo Y, Wang Y, et al. Clinical development of CAR T cell therapy in China: 2020 update[J]. Cell Mol Immunol, 2021, 18(4):792-804.
|
4 |
Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5):449-459.
|
5 |
Hu Y, Wu Z, Luo Y, et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia[J]. Clin Cancer Res, 2017, 23(13):3297-3306.
|
6 |
Cao J, Wang G, Cheng H, et al. Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia[J]. Am J Hematol, 2018, 93(7):851-858.
|
7 |
Pan J, Niu Q, Deng B, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia[J]. Leukemia, 2019, 33(12):2854-2866.
|
8 |
Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Clin Cancer Res, 2021, 27(10):2764-2772.
|
9 |
Jiang H, Li C, Yin P, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial[J]. Am J Hematol, 2019, 94(10):1113-1122.
|
10 |
Chen YH, Zhang X, Cheng YF, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation[J]. Cytotherapy, 2020, 22(12):755-761.
|
11 |
Gu R, Liu F, Zou D, et al. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia[J]. J Hematol Oncol, 2020, 13(1):122.
|
12 |
Pan J, Zuo S, Deng B, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL[J]. Blood, 2020, 135(5):387-391.
|
13 |
Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features[J]. Blood Adv, 2020, 4(10):2325-2338.
|
14 |
Chen W, Ma Y, Shen Z, et al. Humanized anti-CD19 CAR-T cell therapy and sequential allogeneic hematopoietic stem cell transplantation achieved long-term survival in refractory and relapsed B lymphocytic leukemia: a retrospective study of CAR-T cell therapy[J]. Front Immunol, 2021, 12:755549.
|
15 |
Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation[J]. Am J Hematol, 2021, 96(6):671-679.
|
16 |
Tan Y, Cai H, Li C, et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL[J]. Blood Cancer J, 2021, 11(4):71.
|
17 |
Wang S, Wang X, Ye C, et al. Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia[J]. Am J Hematol, 2021, 96(5):E162-E165.
|
18 |
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1):31-42.
|
19 |
Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma[J]. Blood, 2020, 136(14):1632-1644.
|
20 |
Yan ZX, Li L, Wang W, et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin′s lymphoma[J]. Clin Cancer Res, 2019, 25(23):6995-7003.
|
21 |
Sang W, Shi M, Yang J, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma[J]. Cancer Med, 2020, 9(16):5827-5838.
|
22 |
Wei G, Zhang Y, Zhao H, et al. CD19/CD22 dual-targeted CAR T-cell therapy for relapsed/refractory aggressive B-cell lymphoma: a safety and efficacy study[J]. Cancer Immunol Res, 2021, 9(9):1061-1070.
|
23 |
Zhang Y, Wang Y, Liu Y, et al. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial[J]. Leukemia, 2022, 36(1):189-196.
|
24 |
Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J]. J Clin Oncol, 2018, 36(22):2267-2280.
|
25 |
Zhang M, Zhou L, Zhao H, et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy[J]. Clin Cancer Res, 2021, 27(23):6384-6392.
|
26 |
Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2018, 11(1):141.
|
27 |
Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma[J]. J Clin Invest, 2019, 129(6):2210-2221.
|
28 |
Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2019, 380(18):1726-1737.
|
29 |
Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma[J]. Proc Natl Acad Sci U S A, 2019, 116(19):9543-9551.
|
30 |
Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial[J]. Lancet Haematol, 2019, 6(10):e521-e529.
|
31 |
Li C, Cao W, Que Y, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia[J]. Clin Transl Med, 2021, 11(3):e346.
|
32 |
Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2021, 14(1):161.
|
33 |
Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma[J]. Blood, 2021, 137(21):2890-2901.
|
34 |
Mullard A. FDA approves first CAR T therapy[J]. Nat Rev Drug Discov, 2017, 16(10):669.
|
35 |
FDA approves second CAR T-cell therapy[J]. Cancer Discov, 2018, 8(1):5-6.
|
36 |
Hou JZ, Ye JC, Pu JJ, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting[J]. J Hematol Oncol, 2021, 14(1):66.
|
37 |
Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy[J]. Nat Rev Drug Discov, 2021, 20(5):332.
|
38 |
Mullard A. FDA approves fourth CAR-T cell therapy[J]. Nat Rev Drug Discov, 2021, 20(3):166.
|
39 |
Nagle SJ, Murphree C, Raess PW, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies[J]. Am J Hematol, 2021, 96(4):455-461.
|
40 |
Wang L, Hong R, Zhou L, et al. New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia[J]. Front Oncol, 2021, 11:702644.
|
41 |
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967):517-528.
|
42 |
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5):439-448.
|
43 |
Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma[J]. Haematologica, 2021, 106(4):978-986.
|
44 |
Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells[J]. Bone Marrow Transplant, 2019, 54(10):1643-1650.
|
45 |
Liu Y, Liang B, Liu Y, et al. Cytokine release syndrome is an independent risk factor associated with platelet transfusion refractoriness after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia[J]. Front Pharmacol, 2021, 12:702152.
|
46 |
Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions[J]. J Allergy Clin Immunol Pract, 2022, 10(2):460-466.
|
47 |
Wang Y, Li C, Xia J, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma[J]. Blood Adv, 2021, 5(23):5290-5299.
|
48 |
Pan J, Tan Y, Wang G, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial[J]. J Clin Oncol, 2021, 39(30):3340-3351.
|
49 |
Kim MY, Yu KR, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia[J]. Cell, 2018, 173(6):1439-1453.e19.
|
50 |
Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells[J]. Blood, 2014, 123(15):2343-2354.
|
51 |
Shao M, Yu Q, Teng X, et al. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial[J]. Bone Marrow Transplant, 2021, 56(7):1642-1650.
|
52 |
Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies[J]. Biol Blood Marrow Transplant, 2020, 26(5):865-875.
|
53 |
U.S. Food and Drug Administration. YESCARTA®(axicabtagene ciloleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
54 |
U.S. Food and Drug Administration. KYMRIAH®(tisagenlecleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
55 |
U.S. Food and Drug Administration. BREYANZI®(lisocabtagene maraleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
56 |
U.S. Food and Drug Administration. ABECMA®(idecabtagene vicleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
57 |
U.S. Food and Drug Administration. TECARTUS®(brexucabtagene autoleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
58 |
U.S. Food and Drug Administration. CARVYKTI™(ciltacabtagene autoleucel) suspension for intravenous infusion[EB/OL]. [2022-02-01].
URL
|
59 |
Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies[J]. Lancet, 2020, 396(10266):1885-1894.
|
60 |
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1):47-62.
|
61 |
Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma[J]. Signal Transduct Target Ther, 2020, 5(1):134.
|
62 |
Nie J, Yang L, Huang L, et al. Infection complications in febrile chimeric antigen receptor (CAR)-T recipients during the peri-CAR-T cell treatment period examined using metagenomic next-generation sequencing (mNGS)[J]. Cancer Commun (Lond), 2022. [published online ahead of print]
|
63 |
Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies[J]. Blood Adv, 2020, 4(15):3776-3787.
|
64 |
Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma[J]. Blood, 2021, 138(24):2499-2513.
|
65 |
Faude S, Wei J, Muralidharan K, et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse[J]. Blood Adv, 2021, 5(8):2128-2136.
|
66 |
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16):1507-1517.
|
67 |
Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med, 2014, 6(224):224ra25.
|
68 |
Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy[J]. Ann Oncol, 2021, 32(1):34-48.
|
69 |
中华医学会内科学分会, 王建祥, 张奉春, 等. 中国成人血小板减少症诊疗专家共识 [J]. 中华内科杂志, 2020, 59 (7): 498-510.
|
70 |
Bernardes M, Hohl TM. Fungal infections associated with the use of novel immunotherapeutic agents[J]. Curr Clin Microbiol Rep, 2020, 7(4):142-149.
|
71 |
中华医学会血液学分会, 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2020年版)[J]. 中华血液学杂志, 2020, 41(12): 969-978.
|
72 |
Elad S, Raber-Durlacher JE, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT)[J]. Support Care Cancer, 2015, 23(1):223-236.
|
73 |
张佳思, 阮潜瑛, 符刚, 等. 急性白血病患者CAR-T治疗的护理[J]. 护理学杂志, 2018, 33(1):28-30.
|
74 |
糜坚青, 蔡晓红, 王少元, 等. CD38单克隆抗体对输血相容性检测干扰及其应对方案的专家共识[J]. 中国输血杂志, 2021, 34(4):8.
|
75 |
何吉. 血小板配型及相容性输注的专家共识[J]. 2021, 43(13):1367-1371.
|
76 |
急性出血性凝血功能障碍诊治专家共识组. 急性出血性凝血功能障碍诊治专家共识[J]. 中华急诊医学杂志, 2020, 29(6):780-787.
|
77 |
Gaut D, Tang K, Sim MS, et al. Filgrastim associations with CAR T-cell therapy[J]. Int J Cancer, 2021, 148(5):1192-1196.
|
78 |
Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline[J]. J Clin Oncol, 2021, 39(35):3978-3992.
|
79 |
Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol, 2021.
|
80 |
Lin Q, Liu X, Han L, et al. Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA-CAR-T therapy in patient with relapsed myeloma[J]. Bone Marrow Transplant, 2020, 55(6):1203-1205.
|
81 |
Qasrawi A, Arora R, Ramlal R, et al. Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma[J]. Am J Hematol, 2020, 95(4):E89-E91.
|